Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. onsets van immuniteit zijn aangetoond een week na de primaire vaccinatiekuur voor rhinotracheitis, calicivirus, chlamydophila felis en panleucopenie componenten. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals voor felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europese Unie - Nederlands - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals voor felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bioveta a.s. - levend boviene herpesvirus type 1 (bhv1), ge negatief - lyofilisaat en oplosmiddel voor suspensie voor injectie - levend, verzwakt, boviene herpesvirus type 1 (bhv1) - bovine rhinotracheitis virus (ibr) - rund

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

ceva sante animale b.v. - levend verzwakt aviaire metapneumovirus subtype b, stam crr126 - lyofilisaat voor oculonasale suspensie - avian rhinotracheitis virus - kippen

Europese Unie - Nederlands - EMA (European Medicines Agency)

warner chilcott  deutschland gmbh - testosteron - seksuele disfuncties, psychologisch - geslachtshormonen en modulatoren van het genitale systeem, - livensa is geïndiceerd voor de behandeling van hypoactive seksuele begeerte stoornis (hsdd) in bilateraal oophorectomised en gehysterectomeerde (operatief geïnduceerde menopauze) vrouwen ontvangen gelijktijdige oestrogeentherapie.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

elanco europe ltd. - levend verzwakt chlamydophila felis, stam baker; levend verzwakt feliene calicivirus stam f9; levend verzwakt feliene infectieuze rhinotracheÏteitsvirus, stam fvrm; levend verzwakt feliene panleucopenievirus, stam sneeuwluipaard - lyofilisaat voor suspensie voor injectie - feline panleucopenia virus / parvovirus vaccine + feline rhinotracheitis virus vaccine + feline calicivirus vaccine + chlamydia vaccine

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - levend verzwakt chlamydophila felis, stam baker2,3 >= ie/ml; levend verzwakt feliene calicivirus stam f94,6 >= ie/ml; levend verzwakt feliene herpesvirus type 1, stam g2620a5,2 >= ie/ml; levend verzwakt feliene panleucopenievirus, stam mw-14,3 >= ie/ml; hulpstoffen; hulpstoffen:substantieconcentratie; dinatriumwaterstoffosfaat 2-water (e 339); gelatine (e 441); kaliumdiwaterstoffosfaat 0-water (e 340); saccharose; water voor injectie; - lyofilisaat voor suspensie voor injectie - feline panleucopenia virus / parvovirus vaccine + feline rhinotracheitis virus vaccine + feline calicivirus vaccine + chlamydia vaccine